You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

51 Results
Drug
Other Name(s): Herceptin® , Kanjinti™; Ogivri™; Trazimera™; Herzuma®; Ontruzant®
Dec 2024
Drug
Other Name(s): Avastin® , Mvasi®; Zirabev®; Bambevi®; Abevmy®; Aybintio®; Vegzelma™
Nov 2024
Drug
Other Name(s): Velcade®
Nov 2024
Drug
Other Name(s): Torisel ®
Jun 2024
Drug
Other Name(s): Treanda®
Nov 2024
Drug
Other Name(s): Adcetris®
Jun 2025
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
New Drug Funding Program
    Temsirolimus - Metastatic Renal Cell Carcinoma
Jun 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Previously Untreated - Multiple Myeloma
ODB - General Benefit
    melphalan - oral tablets
ODB - General Benefit
    prednisone
May 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Relapsed or Refractory Multiple Myeloma
ODB - General Benefit
    dexamethasone
Nov 2024
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) in combination with Chemotherapy - Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer
May 2024
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Feb 2022
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
New Drug Funding Program
    Bendamustine - First Line - Chronic Lymphocytic Leukemia
Nov 2024

Pages